News

Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialKey PointsQuestion  Is long-term treatment with acoramidis in transthyretin amyloid…

LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory…

Analyses presented at ACC reinforce the totality of data for vutrisiran in patients with ATTR-CM including the impact on cardiovascular outcomes across a range of…

 I would like to attend…Live In Person in New OrleansSaturday, March 28, 20266:30-7:00 AM CDT: Registration & Breakfast7:00-8:00 AM CDT: SymposiumVirtually…

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like…

Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.UK-based biotech Immutrin…

Amyloidosis is a rare disease involving the formation and spread of abnormal proteins in the body. Unlike with other proteins, the body cannot naturally recycle…

PurposeAmyloid positron emission tomography (PET) tracers are increasingly used to detect cardiac amyloidosis (CA). 11C-Pittsburgh compound B (PiB) and 1⁸F-…

Viz.ai has announced a partnership with Alnylam Pharmaceuticals to improve early identification and care coordination for patients with cardiac amyloidosis, a…

Join the CCS for the third and final installment of the Amyloid Education Series 2.0 in the upcoming webinar, ‘Cases and Clinical Conundrums in Amyloidosis…